Evaluation of intraperitoneal hyperthermic chemoperfusion efficiency for chemoresistant ovarian cancer

Dutchak U., Fetsych M.

U. Dutchak, M. Fetsych

Danylo Galytskyj Lviv National Medical University, Lviv, Ukraine

Uliasia3@rambler.ru

Introduction: Intraoperative hyperthermic intraperitoneal chemoperfusion (HIPEC) is a new method of combined treatment of chemoresistant ovarian cancer (OC) with peritoneal carcinomatosis, which efficiency was not fully determined. Aim: To improve the efficiency of treatment of patients with chemoresistant recurrent ovarian cancer after cytoreductive operation with HIPEC. Patients and Methods: We conducted a full clinical examination and treatment of 181 patients with recurrent OC, including 72 patients with chemoresistant recurrent OC. Depending on the treatment of OC, patients were divided into three groups. The first group — 72 patients who received systemic chemotherapy: 1A group — 17 patients with chemoresistant recurrent OC, 1B group — 55 patients with chemosensitive recurrent OC. The second group — 61 patients who underwent cytoreductive operation and systemic chemotherapy: 2A group — 29 patients with chemoresistant recurrent OC, 2B group — 32 patients with chemosensitive recurrent OC. The third group — 48 patients who underwent cytoreductive operation, HIPEC and systemic chemotherapy: 3A group — 26 patients with chemoresistant recurrent OC, 3B group — 22 patients with chemosensitive recurrent OC. Results: http://cialisfromindia-onlinerx.com/ Median of survival for patients, who received combined treatment including cytoreductive operation and HIPEC with systemic chemotherapy, was 27 months and median of survival for patients with chemoresistant recurrent OC, who received treatment including cytoreductive operation with systemic chemotherapy without HIPEC, was 18 months, median of survival for patients, who received treatment with systemic chemotherapy, was 10 months. Procedure of HIPEC didn’t increase the frequency of surgical complications and postoperative lethality in OC patients. Surgical complications after cytoreductive operation and HIPEC was observed in 10 (21%) patients, after cytoreductive operation without HIPEC — in 14 (22.9%) patients. Postoperative lethality after the procedure of HIPEC was observed in 2 (4.2%) patients, and in 3 (4.9%) patients after the procedure of HIPEC. Conclusions: Application of HIPEC in combined treatment of patients with chemoresistant recurrent OC evidently increases survival of patients.

No Comments » Add comments
Leave a comment

ERROR: si-captcha.php plugin says GD image support not detected in PHP!

Contact your web host and ask them why GD image support is not enabled for PHP.

ERROR: si-captcha.php plugin says imagepng function not detected in PHP!

Contact your web host and ask them why imagepng function is not enabled for PHP.